These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18066038)

  • 1. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.
    Subramanian GM; Fiscella M; Lamousé-Smith A; Zeuzem S; McHutchison JG
    Nat Biotechnol; 2007 Dec; 25(12):1411-9. PubMed ID: 18066038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.
    Rustgi VK
    Curr Med Res Opin; 2009 Apr; 25(4):991-1002. PubMed ID: 19275518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Garcia A; Moore PA; Yu R; Subramanian GM
    Antivir Ther; 2006; 11(7):901-8. PubMed ID: 17302252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon monotherapy for chronic hepatitis C.
    Heathcote J; Zeuzem S
    Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
    Sebastiani G; Ferrari A; Boccato S; Pistis R; Alberti A
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1077-82. PubMed ID: 17877515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
    Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
    J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-based therapy of hepatitis C.
    Chevaliez S; Pawlotsky JM
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B.
    Helvaci M; Kizilgunesler A; Kasirga E; Ozbal E; Kuzu M; Sozen G
    J Gastroenterol Hepatol; 2004 Jul; 19(7):785-91. PubMed ID: 15209626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.
    Grebely J; Raffa JD; Meagher C; Duncan F; Genoway KA; Khara M; McLean M; Mead A; Viljoen M; DeVlaming S; Fraser C; Conway B
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1519-25. PubMed ID: 17645460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent trends in the therapy of hepatitis C].
    Meschini A; Lucchetta MC; Fontana M; Nocchi S; Pace A; Grassi M
    Clin Ter; 2003; 154(3):181-91. PubMed ID: 12910808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture.
    Liu C; Zhu H; Subramanian GM; Moore PA; Xu Y; Nelson DR
    Hepatol Res; 2007 Nov; 37(11):941-7. PubMed ID: 17573950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection.
    Jones TD; Hanlon M; Smith BJ; Heise CT; Nayee PD; Sanders DA; Hamilton A; Sweet C; Unitt E; Alexander G; Lo KM; Gillies SD; Carr FJ; Baker MP
    J Interferon Cytokine Res; 2004 Sep; 24(9):560-72. PubMed ID: 15450132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.